Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PainChek Ltd ( (AU:PCK) ) just unveiled an update.
PainChek Limited has been granted a De Novo classification by the U.S. FDA for its PainChek Adult App, which has been formally recognized as a medical device for pain assessment with a new product code ‘SGB’. This significant regulatory milestone is expected to have a material effect on the company’s securities and enhances its market positioning as a leader in pain assessment technology.
More about PainChek Ltd
PainChek Limited operates in the healthcare industry, specializing in the development of medical devices for pain assessment. Its primary product is the PainChek Adult App, which is designed to assess pain levels in individuals who may not be able to communicate effectively.
Average Trading Volume: 4,440,602
Technical Sentiment Signal: Buy
Current Market Cap: A$132.6M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.